South Africa

Population 2018 58 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>301 (215–400)</td>
<td>520 (373–691)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>177 (127–235)</td>
<td>306 (219–406)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>11 (7.2–16)</td>
<td>19 (12–28)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>21 (20–23)</td>
<td>37 (35–39)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>42 (30–57)</td>
<td>73 (51–99)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018
- % tested with rapid diagnostics at time of diagnosis: 71%
- % with known HIV status: 90%
- % pulmonary: 89%
- % bacteriologically confirmed**: 70%
- % children aged 0-14 years: 7%
- % women: 37%
- % men: 56%

Total cases notified: 235 652

Universal health coverage and social protection
- TB treatment coverage (notified/estimated incidence), 2018: 76% (57–110)
- TB case fatality ratio (estimated mortality/estimated incidence), 2018: 22% (14–30)
- TB/HIV care in new and relapse TB patients, 2018:
  - Patients with known HIV status who are HIV-positive: 120 862 (59%)
    - on antiretroviral therapy: 104 625 (87%)

Drug-resistant TB care, 2018
- % of bacteriologically confirmed TB cases tested for rifampicin resistance**: 92%
  - New cases: 92%
  - Previously treated cases: 94%

Laboratory-confirmed cases* MDR/RR-TB: 13 199, XDR-TB: 553
- Patients started on treatment**: MDR/RR-TB: 13 199, XDR-TB: 553

Treatment success rate and cohort size
- New and relapse cases registered in 2017: 77% (74–80)
- Previously treated cases, excluding relapse, registered in 2017: 59% (56–62)
- HIV-positive TB cases registered in 2017: 75% (72–78)
- MDR/RR-TB cases started on second-line treatment in 2016: 54% (50–59)
- XDR-TB cases started on second-line treatment in 2016: 58% (55–62)

TB preventive treatment, 2018
- % of HIV-positive people (newly enrolled in care) on preventive treatment: 65%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 59% (54–65)

TB financing, 2019
- National TB budget (US$ millions): 240
  - Funding source: 87% domestic, 13% international, 0% unfunded

*Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
** MDR/RR-TB: 13 199, XDR-TB: 553

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2019-10-28 Data: www.who.int/tb/data